Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Export

@article{citeulike:851143, abstract = {Colon cancer is one of the carcinomas that is resistant to a variety of therapies. To develop a new therapy by regulating the activated K-ras gene in colon cancers, we prepared synthetic DNA encoding the ribozyme (catalytic RNA), and inserted it into an expression vector (LNCX) originated from a retrovirus. Transfection of the vector into SW620 human colon cancer cells brought about significant suppression of K-ras mRNA synthesis and inhibition of the cell growth. Studies in athymic mice, in which K-ras ribozyme-introduced SW620 cells were transplanted, also revealed a marked reduction of tumor growth in vivo. Furthermore, the ribozyme-introduced tumors became more sensitive to treatment with anti-cancer drugs such as cisplatin, adriamycin, 5-fluorouracil, vincristine, and etoposide. These data suggest that the possible efficacy of anti-K-ras ribozyme increases the chemosensitivity of human colon cancers as well as the inhibitory effect on the growth of human colon cancers.}, address = {Department of Molecular Diagnostics, Tohoku University School of Medicine, Sendai, Japan.}, author = {Funato, T. and Ishii, T. and Kambe, M. and Scanlon, K. J. and Sasaki, T.}, citeulike-article-id = {851143}, citeulike-linkout-0 = {http://dx.doi.org/10.1038/sj.cgt.7700125}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/10766356}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=10766356}, doi = {10.1038/sj.cgt.7700125}, issn = {0929-1903}, journal = {Cancer Gene Ther}, keywords = {5-fu, antisense, cancer, cddp, colon, drug, growth, inhibiton, k-ras, mutation, sensitivity}, month = {March}, number = {3}, pages = {495--500}, posted-at = {2006-09-20 12:11:48}, priority = {5}, title = {Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells.}, url = {http://dx.doi.org/10.1038/sj.cgt.7700125}, volume = {7}, year = {2000} }

TY - JOUR ID - citeulike:851143 L3 - citeulike-article-id:851143 N2 - Colon cancer is one of the carcinomas that is resistant to a variety of therapies. To develop a new therapy by regulating the activated K-ras gene in colon cancers, we prepared synthetic DNA encoding the ribozyme (catalytic RNA), and inserted it into an expression vector (LNCX) originated from a retrovirus. Transfection of the vector into SW620 human colon cancer cells brought about significant suppression of K-ras mRNA synthesis and inhibition of the cell growth. Studies in athymic mice, in which K-ras ribozyme-introduced SW620 cells were transplanted, also revealed a marked reduction of tumor growth in vivo. Furthermore, the ribozyme-introduced tumors became more sensitive to treatment with anti-cancer drugs such as cisplatin, adriamycin, 5-fluorouracil, vincristine, and etoposide. These data suggest that the possible efficacy of anti-K-ras ribozyme increases the chemosensitivity of human colon cancers as well as the inhibitory effect on the growth of human colon cancers. IS - 3 JF - Cancer Gene Ther SN - 0929-1903 AD - Department of Molecular Diagnostics, Tohoku University School of Medicine, Sendai, Japan. EP - 500 TI - Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. VL - 7 SP - 495 KW - 5-fu KW - antisense KW - cancer KW - cddp KW - colon KW - drug KW - growth KW - inhibiton KW - k-ras KW - mutation KW - sensitivity AU - Funato, T AU - Ishii, T AU - Kambe, M AU - Scanlon, KJ AU - Sasaki, T PY - 2000/03// UR - http://dx.doi.org/10.1038/sj.cgt.7700125 ER -